Enanta Pharmaceuticals (NASDAQ:ENTA) Insider Brendan Luu Sells 1,394 Shares

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) insider Brendan Luu sold 1,394 shares of the company’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $14.23, for a total transaction of $19,836.62. Following the completion of the sale, the insider directly owned 38,329 shares of the company’s stock, valued at $545,421.67. This trade represents a 3.51% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Enanta Pharmaceuticals Stock Up 3.6%

Shares of NASDAQ:ENTA opened at $14.60 on Friday. The stock has a market cap of $421.36 million, a PE ratio of -3.81 and a beta of 0.96. The company’s fifty day moving average is $11.89 and its 200 day moving average is $9.04. Enanta Pharmaceuticals, Inc. has a 52 week low of $4.09 and a 52 week high of $15.34.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Monday, November 17th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.13) by $0.26. Enanta Pharmaceuticals had a negative net margin of 125.36% and a negative return on equity of 93.76%. The business had revenue of $15.13 million during the quarter, compared to analyst estimates of $15.60 million. Sell-side analysts anticipate that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently weighed in on ENTA. Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Wednesday, October 8th. JPMorgan Chase & Co. assumed coverage on Enanta Pharmaceuticals in a research note on Friday, November 14th. They set an “overweight” rating and a $17.00 price objective for the company. Jefferies Financial Group upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and raised their target price for the stock from $14.00 to $20.00 in a report on Wednesday, October 1st. JMP Securities lifted their target price on shares of Enanta Pharmaceuticals from $24.00 to $25.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 12th. Finally, Evercore ISI lowered their price target on shares of Enanta Pharmaceuticals from $20.00 to $12.00 and set an “outperform” rating for the company in a report on Monday, September 15th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $20.33.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Farther Finance Advisors LLC grew its position in shares of Enanta Pharmaceuticals by 11,558.0% in the 2nd quarter. Farther Finance Advisors LLC now owns 5,829 shares of the biotechnology company’s stock worth $44,000 after buying an additional 5,779 shares during the last quarter. US Bancorp DE bought a new position in shares of Enanta Pharmaceuticals during the first quarter valued at approximately $36,000. Quarry LP bought a new position in shares of Enanta Pharmaceuticals during the third quarter valued at approximately $81,000. China Universal Asset Management Co. Ltd. lifted its stake in Enanta Pharmaceuticals by 103.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,747 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 4,454 shares during the period. Finally, AlphaQuest LLC boosted its holdings in Enanta Pharmaceuticals by 18.1% in the third quarter. AlphaQuest LLC now owns 10,198 shares of the biotechnology company’s stock valued at $122,000 after acquiring an additional 1,562 shares in the last quarter. Hedge funds and other institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.